Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK\u00ae in Combination with Rituximab in Patients with B-c

• click to rate

  Posted by Two Blokes Apr 28 - Filed in Stock - 2 views
  
  Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK\u00ae + rituximab for the treatment of B-cell driven diseases in a community setting